A comprehensive timeline of NutraBiotech's research compound programs from 2013 to 2026. From PDE5 inhibitors and SARMs to NAD+ boosters and next-generation oncology agents — explore our portfolio and partner with us for custom synthesis.
NutraBiotech is proud to announce two flagship research programs for 2026, representing the culmination of years of synthesis optimization, quality refinement, and application development. These compounds are produced at our ISO-certified manufacturing facilities and offered with comprehensive analytical documentation, competitive pricing, and dedicated technical support.
ISRIB A-17 (CAS 1628478-15-8) is a second-generation integrated stress response inhibitor that targets the PERK/eIF2α pathway with unprecedented potency. Building on the foundational ISRIB trans-isomer program initiated in 2018, ISRIB A-17 represents a major leap forward in pharmacological performance.
NRH — Dihydronicotinamide Riboside — is the reduced form of nicotinamide riboside (NR) and represents the most advanced NAD+ precursor in NutraBiotech's portfolio. Discovered through our internal NAD+ booster research program, NRH enters cells via a unique adenosine kinase (ADK) salvage pathway, bypassing the rate-limiting NAMPT step that constrains NMN and NR metabolism.
NutraBiotech has continuously expanded its research compound portfolio since 2013. Below is a chronological overview of our featured programs by year, showcasing the breadth and depth of our chemical synthesis capabilities across multiple therapeutic areas and research domains.
In 2022, NutraBiotech launched a dedicated Custom Synthesis Inhibitor Programs initiative featuring 20 high-value small-molecule inhibitors and agonists targeting diverse therapeutic areas. Each compound is available as a reference standard or through custom synthesis with full analytical characterization (NMR, HPLC, HRMS, elemental analysis) and batch-specific Certificates of Analysis.
| # | Compound | CAS Number | Description |
|---|---|---|---|
| 1 | Ponesimod | 854107-55-4 | Potent oral bioavailable S1P1 agonist for multiple sclerosis and immune regulation research |
| 2 | SB-334867 | 792173-99-0 | Potent orexin 1 receptor antagonist for sleep disorder and neurobehavioral research |
| 3 | AG-636 | 1623416-31-8 | Potent orally active DHODH inhibitor for lymphoma and hematological malignancy research |
| 4 | GDC-0077 (Inavolisib) | 2060571-02-8 | Potent oral bioavailable PI3Kα inhibitor for mutant PIK3CA breast cancer research |
| 5 | BDP9066 | 2226507-04-4 | Potent Cdc42-binding kinase inhibitor for glioblastoma and tumor invasion research |
| 6 | Oliceridine | 1401031-39-7 | Potent G-protein biased mu-opioid agonist for postoperative acute pain and anesthetic research |
| 7 | GSK2881078 | 1539314-06-1 | Potent oral bioavailable SARM androgen receptor agonist for muscle wasting and cachexia research |
| 8 | Pluripotin (SC1) | 839707-37-8 | Potent dual ERK1 and RasGAP inhibitor for embryonic stem cell self-renewal and oncology research |
| 9 | GSK620 | 2088410-46-0 | Potent orally active pan-BD2 inhibitor for BET bromodomain and inflammatory research |
| 10 | SNDX-5613 (Revumenib) | 2169919-21-3 | Potent Menin-MLL PPI inhibitor for MLL-r AML and ALL leukemia research |
| 11 | GM6001 (Ilomastat) | 142880-36-2 | Potent matrix metalloproteinase inhibitor for anti-inflammation and tumor invasion research |
| 12 | YC-1 | 170632-47-0 | Potent HIF-1α and sGC activator for anti-angiogenesis and oncology research |
| 13 | GSK1016790A | 942206-85-1 | Potent TRPV4 agonist for ion channel and physiological research |
| 14 | UVI 3003 | 847239-17-2 | Potent retinoid X receptor alpha antagonist for lipid metabolism and developmental biology research |
| 15 | Licogliflozin (LIK066) | 1291094-73-9 | Potent oral dual SGLT inhibitor for diabetes and obesity research |
| 16 | JH-X-119-01 | 2227368-54-7 | Potent irreversible IRAK1 inhibitor for inflammation and lymphoma research |
| 17 | GKN-43736 | 486443-73-6 | Potent mutant HTT degrader targeting HTT-LC3 interaction for neurodegenerative research |
| 18 | DDO-5936 | 2355377-13-6 | Potent selective Hsp90-Cdc37 PPI inhibitor for colorectal cancer research |
| 19 | SEN-12333 (WAY-317538) | 874450-44-9 | Orally active dual α7 nAChR agonist and H3 antagonist for cognitive and neuroinflammation research |
| 20 | YKL-5-124 | 1957203-01-8 | Potent irreversible CDK7 inhibitor for cell cycle regulation and oncology research |
NutraBiotech's R&D pipeline is continuously expanding. The following compounds are currently in development and scheduled for release in upcoming program cycles. Subscribe to our newsletter or follow us on social media to receive launch notifications.
| # | Compound | Research Area / Expected Application |
|---|---|---|
| 1 | CC90001 | Novel cereblon modulator; protein degradation and targeted therapy research |
| 2 | BDP9066 | See Inhibitor Programs 2022 above — scale-up production in progress |
| 3 | GDC-007 | PI3K pathway inhibitor; oncology and cell signaling research |
| 4 | CAY10594 | Selective kinase inhibitor; signal transduction and cancer biology research |
| 5 | Danicamtiv | Cardiac myosin activator; heart failure and cardiovascular research |
| 6 | CRT0273750 | Novel therapeutic target compound; inflammation and immunology research |
| 7 | FH535 | Wnt/β-catenin pathway inhibitor; cancer stem cell and developmental biology research |
| 8 | SB-334867 | See Inhibitor Programs 2022 above — dedicated program launch pending |
| 9 | Desidustat | HIF prolyl hydroxylase inhibitor; anemia and hypoxia research |
Beyond our featured programs, NutraBiotech offers comprehensive custom synthesis services for research compounds not listed in our current catalog. Whether you need a novel molecule, a specific metabolite, a stable isotope-labeled analog, or an impurity reference standard, our experienced chemistry team can deliver.
A complete, sortable index of all NutraBiotech featured programs from 2013 through 2026. Use this reference table to quickly locate any compound by year, name, or CAS number.
| Year | Compound | CAS Number | Category / Target |
|---|---|---|---|
| 2013 | Mirodenafil | N/A | PDE5 Inhibitor |
| 2013 | Sunifiram | 314728-85-3 | Nootropic / AMPA Modulator |
| 2014 | RU58841 (PSK-3841) | N/A | Non-Steroidal Antiandrogen (NSAA) |
| 2014 | Fasoracetam | 110958-19-5 | Nootropic / mGluR Modulator |
| 2014 | NSI-189 Phosphate | 1270138-41-4 | Neurogenic / Antidepressant Research |
| 2014 | Pirfenidone | N/A | Antifibrotic / TGF-β Inhibitor |
| 2014 | Coluracetam | 135463-81-9 | Nootropic / HACU Enhancer |
| 2015 | NSI-189 Free Base | 1270138-40-3 | Neurogenic / Antidepressant Research |
| 2016 | NMN (β-Nicotinamide Mononucleotide) | 1341-23-7 | NAD+ Precursor |
| 2017 | Tideglusib (NP-12) | N/A | GSK-3 Inhibitor |
| 2018 | ACP-105 | N/A | SARM |
| 2018 | PRL-8-53 | 51352-87-5 | Nootropic / Memory Enhancement |
| 2018 | ISRIB Trans-isomer | N/A | ISR Inhibitor / PERK Antagonist |
| 2019 | GS-441524 | N/A | Nucleoside Analog Antiviral |
| 2019 | Buckminsterfullerene (C60) | N/A | Fullerene / Antioxidant |
| 2020 | Ebselen | N/A | Anti-Inflammatory / GPx Mimetic |
| 2021 | SM04554 | 1360540-81-3 | Wnt/β-Catenin Modulator |
| 2021 | Fevipiprant | 872365-14-5 | CRTH2/DP2 Antagonist |
| 2021 | 7,8-Dihydroxyflavone | 38183-03-8 | TrkB Agonist |
| 2022 | Urolithin A | 1143-70-0 | Mitophagy Activator / Natural Product |
| 2022 | Urolithin B | 1139-83-9 | Natural Product / Mitochondrial Health |
| 2023 | 4-DMA-7,8-DHF | 1205548-00-0 | TrkB Agonist (Enhanced Bioavailability) |
| 2023 | WAY-200070 | 440122-66-7 | ERβ Agonist |
| 2023 | GTS-21 (DMXB-A) | 156223-05-1 | α7-nAChR Agonist |
| 2024 | Trans-3,5-dimethoxystilbene-4′-O-β-D-glucopyranoside | N/A | Natural Product / Polyphenol Antioxidant |
| 2025 | Valsartan | N/A | ARB / Cardiovascular |
| 2025 | Ciclopirox | N/A | Antifungal / Iron Chelator |
| 2025 | Aciclovir | N/A | Nucleoside Analog Antiviral |
| 2025 | Ganciclovir | N/A | Nucleoside Analog Antiviral (CMV) |
| 2026 | ★ ISRIB A-17 | 1628478-15-8 | PERK/eIF2α ISR Inhibitor (EC50 0.6nM) |
| 2026 | ★ NRH (Dihydronicotinamide Riboside) | N/A | NAD+ Precursor / ADK Pathway |
Whether you need reference standards from our featured programs, custom synthesis of novel compounds, or bulk quantities of ISRIB A-17 and NRH — our team is ready to support your research.
💬 Contact Sales TeamNutraBiotech's Featured Programs are curated research compound portfolios spanning 2013 to 2026. Each program focuses on a specific compound or compound class — including PDE5 inhibitors, SARMs, NAD+ precursors (NMN, NR, NRH), oncology inhibitors, nootropics, natural products (Urolithin A/B), and more. Programs range from reference standards and analytical-grade materials to custom synthesis projects for pharmaceutical research. All products are Research Chemicals intended for laboratory and research use only.
NutraBiotech's 2026 flagship programs are ISRIB A-17 (CAS 1628478-15-8) and NRH — Dihydronicotinamide Riboside. ISRIB A-17 is a next-generation PERK inhibitor with an EC50 of 0.6nM — approximately 10× more potent than the original ISRIB trans-isomer — designed for neurodegenerative disease and cognitive enhancement research. NRH is a reduced-form NAD+ precursor that enters cells via a unique adenosine kinase (ADK) pathway, demonstrating 2–5× superior NAD+ elevation compared to NMN and NR. As a direct manufacturer, NutraBiotech offers both compounds with complete analytical documentation at 30–50% below competitor pricing.
Yes. Custom synthesis is a core service at NutraBiotech. Our chemistry team handles multi-step organic synthesis from milligram to kilogram scale, with full purification (preparative HPLC, flash chromatography, recrystallization) and comprehensive analytical characterization (NMR, HRMS, HPLC, elemental analysis). We also offer salt form optimization, isotopic labeling (13C, 2H, 15N), metabolite synthesis, and impurity standard preparation. All custom projects are protected by NDA. Contact us with your target compound for a confidential quotation (typically within 2–3 business days).
To purchase, contact our sales team via email or phone. Specify the program compound(s) of interest, desired quantity, and delivery destination. We will provide a proforma invoice with complete pricing, available shipping methods, and payment instructions. Direct online ordering is not available as all products are Research Chemicals. Please see our Shipping page for worldwide delivery options and our Payment page for accepted payment methods (Bank Transfer, Western Union, MoneyGram, Alipay, Letter of Credit).
Every batch from NutraBiotech's programs ships with a comprehensive analytical package: Certificate of Analysis (COA) with HPLC purity data, NMR spectrum (1H and/or 13C), HRMS (High-Resolution Mass Spectrometry) data, and elemental analysis where applicable. Additional documentation — including MSDS/SDS, stability data, storage recommendations, and solubility information — is also provided. For custom synthesis projects, the analytical package is tailored to your specifications.
Sample quantities of most program compounds (typically 10–100 mg) are available for evaluation purposes. Samples are provided with full analytical documentation (COA, HPLC, NMR). Sample shipping costs are typically covered by the buyer. For custom synthesis projects, small-scale trial syntheses (10–100 mg) can be arranged before committing to a full-scale production run. Contact our sales team to discuss your evaluation needs.
Compounds listed under Upcoming Programs are currently in active R&D and production scale-up at NutraBiotech. If you are interested in an upcoming program, contact our sales team to express interest. Early partners receive priority access when the program launches and preferential introductory pricing. We also welcome input on purity specifications, preferred salt forms, packaging requirements, and analytical parameters to ensure the product meets your research needs upon release.
No. All NutraBiotech program compounds are Research Chemicals intended exclusively for laboratory and in-vitro research purposes. They are not manufactured under GMP-for-human-use standards, are not sterile, and are not approved by the FDA, EMA, or any other regulatory agency for human or animal administration. They must not be used as active pharmaceutical ingredients (APIs), dietary supplements, food additives, cosmetics, or for any diagnostic or therapeutic purpose. By purchasing, you acknowledge and agree that the products will be used solely for legitimate scientific research.